Sociedad Americana de Hirudoterapia

Venous Congestion in Surgical Flaps

FDA-cleared application: medicinal leech therapy to relieve venous congestion in compromised tissue flaps awaiting vascular ingrowth.

Tier A — FDA-cleared indicationIndicación de dispositivo autorizada por FDALast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?
Yes — FDA-cleared under K040187 (June 21, 2004) for medicinal leech application to relieve venous congestion in microsurgical reconstructive procedures.
¿Qué evidencia existe?
This is the one situation where the FDA has officially cleared medicinal leeches as a medical device. Hospital studies (retrospective series totaling 400+ patients) show that when leech therapy is started within 24 hours of congestion, 70 to 85 percent of threatened flaps survive that would otherwise have been lost. It does not work for flaps with poor artery blood flow — that is a surgical problem leeches cannot solve.
Riesgos principales
  • Heavy bleeding from the bite site for 6 to 10 hours after each leech detaches
  • Need for a blood transfusion if many leeches are used over several days (about 1 in 5 to 1 in 3 patients)
  • Aeromonas hydrophila infection from the leech's gut bacteria (your team gives a preventive antibiotic such as ciprofloxacin)
  • Loss of the flap anyway if the underlying artery problem cannot be fixed
  • Allergic reaction to leech saliva proteins (rare but possible)
  • Scarring from the bite marks once they heal
Quién no debería considerar esto
  • Patients on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, or heparin
  • People with hemophilia or any inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL) who cannot tolerate more blood loss
  • Patients with an active bloodstream infection or sepsis
  • Patients allergic to ciprofloxacin or other antibiotics needed to prevent Aeromonas infection
  • Patients whose flap has lost arterial blood supply (this needs surgical repair first, not leeches)
Qué preguntar a su clínico
  • Is the problem with my flap a vein issue or an artery issue? Leeches only help with vein problems.
  • What antibiotic will I get to prevent Aeromonas infection, and how long will I take it?
  • How often will my blood count be checked, and at what hemoglobin level would you transfuse me?
  • What is the expected timeline — how many days of leech therapy do you estimate before the flap can drain on its own?
  • What signs should my family and I watch for that would mean the treatment is not working?
  • Who is responsible for placing and removing the leeches, and how often will they check on me?
  • What happens to the used leeches afterward, and is there any disposal concern?
Cuándo buscar atención urgente
  • Bleeding from a bite site that soaks through more than one dressing per hour, or any bleeding lasting more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, or pus around the bite area or the flap
  • Fever over 38.0 C / 100.4 F or chills
  • The flap becoming darker, colder, or harder despite leech therapy
  • Hives, swelling of the face or tongue, difficulty breathing, or any sign of allergic reaction

Qué NO significa esto

  • It does not mean the flap is guaranteed to survive — even with leeches, about 15 to 30 percent of severely congested flaps are still lost, usually because of an artery problem that leeches cannot fix.
  • It does not mean leeches cure anything by themselves — they buy time (about 3 to 7 days) while your body grows new veins into the flap.
  • It does not mean this is a treatment you can do at home — it is an inpatient hospital therapy with continuous monitoring of blood counts.
  • It does not mean medicinal leeches are the same as wild leeches — they are FDA-cleared, lab-raised under sterile conditions, and used only once.

Clinical Profile

Category
surgical reconstruction
ICD-10
T87.40, T87.41, T87.42, T87.43, T87.44, I87.8
Safety tier
high

Evidence Summary

Venous congestion in pedicled and free flaps is the most common cause of postoperative flap failure, occurring in 5-10% of microsurgical reconstructions. Hirudo medicinalis received FDA clearance (K040187, June 21 2004) specifically for relief of venous congestion. The mechanism is twofold: mechanical drainage from the bite wound (oozing for 6-10 hours after detachment) and pharmacologic action of hirudin, calin, and hyaluronidase reducing local thrombogenesis. Multiple retrospective series demonstrate flap salvage rates of 70-85% when initiated within 24 hours of congestion onset. Failure to thrive remains driven by arterial compromise (which leeches cannot address) and delayed initiation.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Whitaker IS et al. (2012), n=277 · PMID 22407551 · ASH analysis →
  2. Nguyen MQ et al. (2012), n=39 · PMID 22473683 · ASH analysis →
  3. Chepeha DB et al. (2002), n=8 · PMID 12162779 · ASH analysis →
Sample sizes of key trials for Venous Congestion in Surgical FlapsWhitaker IS et al. 2012277Nguyen MQ et al. 201239Chepeha DB et al. 20028
Participants per key trial (n). Larger trials generally carry more statistical weight; case series with unspecified counts are omitted.
Study-design composition of the evidence base for Venous Congestion in Surgical Flaps3studies
  • Systematic Review: 1 (33%)
  • Cohort: 1 (33%)
  • Case Series: 1 (33%)
Composition of the cited evidence base by study design, from strongest (meta-analysis, systematic review) to weakest (case report). A base weighted toward RCTs and reviews is more reliable.

Detailed Trial Entries

19 trials indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Arterial insufficiency to the flap (must address before leeching)
  • Patient unable to consent to potential transfusion requirement

Related ASH Compounds

Leech-derived molecules implicated in this condition, each profiled in the ASH compound registry:

Related Conditions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Venous Congestion in Surgical Flaps — Hirudotherapy Evidence | ASH